News

A new small molecule, called VOMG, showed good antimicrobial activity against Mycobacterium abscessus, a bacterium that can cause serious infections in people with cystic fibrosis (CF). “The bactericidal and eradicating properties of VOMG … strongly reinforce the potential of VOMG in the treatment of pulmonary infections especially in CF individuals,…

A high dose of vitamin D combined with inulin, a prebiotic, led to improvements in the diversity of bacteria living in the airway and lungs of people with cystic fibrosis (CF) in a small clinical trial. The findings in the study, “Impact of high-dose cholecalciferol (vitamin…

While physical health and life quality gains can be evident in people using CFTR modulators, a group of disease-modifying therapies for cystic fibrosis (CF), their mental well-being needs more attention, according to the Wellness in the Modulator Era (Well-ME) study. Nearly 1 in every 4 patients reported poorer…

Men and patients diagnosed with cystic fibrosis (CF) earlier in life have higher lung function and greater lung function variability, according an analysis spanning over 20 years of data from the U.K. Cystic Fibrosis Registry. Lung function variability increased in men and women with CF after age 40, a…

A researcher at the University of California, Los Angeles (UCLA) has been awarded the Elizabeth Nash Postdoctoral Fellowship to develop a targeted cystic fibrosis (CF) gene therapy delivery system, the university announced. The two-year, $65,000-per-year fellowship, awarded annually by the Cystic Fibrosis Research Institute to support new…

An Emory University program has been awarded $2 million toward optimizing the effectiveness of U.S. newborn screening programs, which help identify serious health conditions such as cystic fibrosis (CF) at birth. The four-year funding opportunity comes through a cooperative agreement with the U.S. Health Resources and Services Administration…

Researchers have uncovered a mechanism by which Pseudomonas aeruginosa and Aspergillus fumigatus — two common infection-causing microbes in the lungs of people with cystic fibrosis (CF) — are able to…

SARS-CoV-2, the virus that causes COVID-19, appears to induce the loss of CFTR protein in a cell-based airway model, replicating the inflammatory state seen in the lungs of people with cystic fibrosis (CF), a study suggested. Treating cells with cardiac glycosides, a class of medicines that block the virus…

Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). The program will test the potency of an experimental treatment known as XF-73 in MRSA samples from CF…

The first healthy volunteers have been dosed in Australia as part of two separate Phase 1 clinical trials of SION-719 and SION-451 — two second-generation NBD1 stabilizers that Sionna Therapeutics is developing to restore function to the CFTR protein, which is faulty in cystic fibrosis (CF). The goal…